SAMSUNG PHARM. Co., LTD. Statistics
Total Valuation
SAMSUNG PHARM. Co., LTD. has a market cap or net worth of KRW 144.95 billion.
Market Cap | 144.95B |
Enterprise Value | n/a |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
SAMSUNG PHARM. Co., LTD. has 94.12 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 94.12M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | -6.93% |
Owned by Insiders (%) | 0.01% |
Owned by Institutions (%) | 4.63% |
Float | 84.26M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 2.02 |
PB Ratio | 0.67 |
P/TBV Ratio | 1.08 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.11.
Current Ratio | 2.38 |
Quick Ratio | 1.38 |
Debt / Equity | 0.11 |
Debt / EBITDA | n/a |
Debt / FCF | -0.97 |
Interest Coverage | -11.20 |
Financial Efficiency
Return on equity (ROE) is -4.40% and return on invested capital (ROIC) is -3.60%.
Return on Equity (ROE) | -4.40% |
Return on Assets (ROA) | -3.34% |
Return on Capital (ROIC) | -3.60% |
Revenue Per Employee | 186.06M |
Profits Per Employee | -24.83M |
Employee Count | 240 |
Asset Turnover | 0.27 |
Inventory Turnover | 2.89 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.77% in the last 52 weeks. The beta is 0.93, so SAMSUNG PHARM. Co., LTD.'s price volatility has been similar to the market average.
Beta (5Y) | 0.93 |
52-Week Price Change | -22.77% |
50-Day Moving Average | 1,589.48 |
200-Day Moving Average | 1,654.60 |
Relative Strength Index (RSI) | 48.18 |
Average Volume (20 Days) | 428,119 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SAMSUNG PHARM. Co., LTD. had revenue of KRW 44.65 billion and -5.96 billion in losses. Loss per share was -101.96.
Revenue | 44.65B |
Gross Profit | 8.02B |
Operating Income | -8.77B |
Pretax Income | -5.90B |
Net Income | -5.96B |
EBITDA | -4.67B |
EBIT | -8.77B |
Loss Per Share | -101.96 |
Balance Sheet
The company has 11.22 billion in cash and 14.28 billion in debt, giving a net cash position of -3.06 billion or -32.53 per share.
Cash & Cash Equivalents | 11.22B |
Total Debt | 14.28B |
Net Cash | -3.06B |
Net Cash Per Share | -32.53 |
Equity (Book Value) | 134.01B |
Book Value Per Share | 2,288.01 |
Working Capital | 30.30B |
Cash Flow
In the last 12 months, operating cash flow was -6.42 billion and capital expenditures -8.31 billion, giving a free cash flow of -14.73 billion.
Operating Cash Flow | -6.42B |
Capital Expenditures | -8.31B |
Free Cash Flow | -14.73B |
FCF Per Share | -156.47 |
Margins
Gross margin is 17.96%, with operating and profit margins of -19.63% and -13.34%.
Gross Margin | 17.96% |
Operating Margin | -19.63% |
Pretax Margin | -13.21% |
Profit Margin | -13.34% |
EBITDA Margin | -10.47% |
EBIT Margin | -19.63% |
FCF Margin | n/a |
Dividends & Yields
SAMSUNG PHARM. Co., LTD. does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -24.91% |
Shareholder Yield | -24.91% |
Earnings Yield | -6.62% |
FCF Yield | -10.16% |
Stock Splits
The last stock split was on April 26, 1995. It was a forward split with a ratio of 1.1.
Last Split Date | Apr 26, 1995 |
Split Type | Forward |
Split Ratio | 1.1 |
Scores
SAMSUNG PHARM. Co., LTD. has an Altman Z-Score of 4.08.
Altman Z-Score | 4.08 |
Piotroski F-Score | n/a |